Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed malignant pleural mesothelioma (MPM) (Epithelioid or biphasic subtype for Phase II patients; epithelioid subtype only for Phase III patients)
Life expectancy of at least 3 months in the opinion of the investigator
Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
Measurable disease according to modified RECIST (Response Evaluation Criteria In Solid Tumours) criteria
You may not be if
Previous systemic chemotherapy for MPM
Prior treatment with nintedanib or any other prior line of therapy
Phase II patients with sarcomatoid subtype MPM or Phase III patients with biphasic or sarcomatoid subtype MPM
Patients with symptomatic neuropathy
Radiotherapy (except extremities) within 3 months prior to baseline imaging
Active brain metastases (e.g. stable for \< 4 weeks)
Radiographic evidence of cavitary or necrotic tumours or local invasion of major blood vessels by MPM
Significant cardiovascular diseases
Inadequate hematologic, renal, or hepatic function
Clareo Health | Nintedanib (BIBF 1120) in Mesothelioma
